We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
We recently published a list of 11 Best NYSE Penny Stocks to Buy Right Now. In this article, we are going to take a look at where Nuvation Bio Inc. (NYSE:NUVB) stands against other best NYSE penny stocks to buy right now.
Small and medium-sized companies are the most affected by the direction of the economy and interest rates. With the US Federal Reserve cutting interest rates and the economy steering into a soft landing, the focus is slowly shifting towards penny stocks that remain well-positioned to be supercharged by improving macroeconomics.
It’s time to go all in into the small-cap rotation play after years of market domination by large-cap stocks. That’s the sentiment echoed by Citi U.S. equity strategist Scott Chronert, who believes small-cap stocks offer an affordable way of investing in value and are well-poised to generate long-term value.
“Combined, investors could be paying a much lower multiple for a similar growth profile going forward,” he wrote. “Given post-pandemic peculiarities, the lack of a real cycle, and secular trends that support leaders, we still want to be owners of some Large Cap winners, but increasingly view Small/Mid Cap as an attractive alternative to the other 493. Said differently, we are more comfortable dipping down cap in search of fundamental winners and thematic expressions.”
Although small and mid-cap stocks have delivered above-average, double-digit gains over the past year, they look increasingly attractive amid a monetary policy change. The US Federal Reserve, commencing its monetary easing cycle, is making it easier for such companies to borrow money to expand their businesses. With their long-term prospects looking positive, investors are slowly taking note of their depressed valuation.
Similarly, the Russell 2000 ETF, which consists mainly of small and medium-cap companies, is up by 13% compared to a 22% gain for the S&P 500, affirming the massive room for gains among penny stocks.
“We continue to believe that these stocks have been unfairly punished (or ignored) given what we have viewed as a mismatch between the fundamental underpinnings and the group’s relative performance, and nothing has changed in that regard. It is only a matter of time before the fortunes of this group take a turn for the better” now that central bankers are cutting rates. Wrote BMO analysts’ research notes to investors.
Likewise, there is an influx of investments into small-cap exchange-traded funds amid growing optimism that the companies are fairly valued with tremendous upside potential. According to ETF journalist Dave Nadig in an interview on CNBC, money inflow into penny stocks might not necessarily be a rotation from winning growth trades. Instead, it is a diversification play as the focus shifts to getting broader exposure heading into year-end. The diversification strategy is part of a broader strategy of absorbing volatility
″ [Investors] are now, for the first time in ages, buying value, buying some of these defensive sectors, buying small caps. But they haven’t stopped buying the other things as well,” Nadig said in an interview on CNBC ETF Edge. “I think this is money coming in from that giant bucket of money markets that we know is sitting out there.”
Given that large-cap stocks continue to outperform the overall market, the focus on penny stocks is mostly on companies that are profitable. Given that 40% of the small-cap companies in the S&P 500 are unprofitable, investors are turning their attention to ETFs that exclude unprofitable companies as they optimize their return amid the current Bull Run.
The focus on penny stocks of profitable companies stems from the historical thesis that small caps often outperform large caps whenever the economy is expanding amid solid macroeconomics. Consequently, small-cap companies with exposure to emerging technologies such as artificial intelligence are becoming some of the most sought-after owing to their tremendous upside potential.
The best NYSE penny stocks to buy right now also stand out owing to their attractive valuations and the fact that they have a narrow expected earnings growth gap compared to large-cap companies. The fact that investors have to pay a much lower multiple for the penny stocks also makes them stand out on the risk-reward front.
Our Methodology
We used the Finviz screener to find stocks lists on the New York Stock Exchange that are trading below $5, as of October 31. We then selected stocks that analysts are bullish on and expect to generate significant long-term value due to their solid underlying fundamentals. Finally, we ranked the stocks in ascending order based on the number of hedge funds that hold stakes in them, as of Q2 2024.
At Insider Monkey, we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
Nuvation Bio Inc. (NUVB): Promising Penny Stock with Strong Oncology Pipeline
A close-up of researchers, carefully studying a biopharmaceutical compound in a laboratory.
Nuvation Bio Inc. (NYSE:NUVB) is a clinical-stage biopharmaceutical company that develops therapeutic candidates for oncology. Its lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation. It is one of the best NYSE penny stocks to buy right now, going by its robust pipeline of drug candidates in various stages of development targeting unmet medical needs.
Taletrectinib is a candidate drug that has already shown competitive efficacy and safety in clinical trials on the treatment of non-small cell lung cancer. Nuvation Bio Inc. (NYSE:NUVB) is submitting a new drug application for the candidate drug as it aims to commercialize it as early as next year upon regulatory approval.
The positive clinical data indicate the strong potential for Taletrectinib to generate long-term shareholder value. Likewise, Nuvation Bio Inc. (NYSE:NUVB) addresses unmet medical needs in oncology and rare disease positions for long-term success.
Overall, NUVB ranks 2nd on our list of best NYSE penny stocks to buy right now. While we acknowledge the potential of NUVB as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than NUVB but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
